Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 111 entries
View as:

A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM

Phase: N/A Priority: Normal
NCT ID: NCT03646721 Org: User:
Start: 08/29/18 End: 05/07/20 Due: 05/07/21

A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg

Phase: N/A Priority: Normal
NCT ID: NCT04653779 Org: User:
Start: 12/31/20 End: 07/31/21 Due: 07/31/22

Pharmacokinetics and Safety Profiles After Administration of DA-5218 and Co-administration of DA-5218-R1, DA-5218-R2 and DA-5218-R3 in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05449704 Org: User:
Start: 07/08/22 End: 09/07/22 Due: 09/07/23

Bioequivalence Study Between "DA-5209 Tab" and "Lixiana Tab"

Phase: N/A Priority: Normal
NCT ID: NCT04671316 Org: User:
Start: 11/23/20 End: 02/04/21 Due: 02/04/22

Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH

Phase: N/A Priority: Normal
NCT ID: NCT02304198 Org: User:
Start: 04/30/14 End: 02/29/16 Due: 02/28/17

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04473417 Org: User:
Start: 08/04/20 End: 10/12/20 Due: 10/12/21

Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fed State

Phase: N/A Priority: Normal
NCT ID: NCT05739877 Org: User:
Start: 03/17/23 End: 04/07/23 Due: 04/07/24

A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin

Phase: N/A Priority: Normal
NCT ID: NCT02946541 Org: User:
Start: 07/31/13 End: 04/30/15 Due: 04/30/16

Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg

Phase: N/A Priority: Normal
NCT ID: NCT02753803 Org: User:
Start: 07/27/16 End: 03/10/17 Due: 03/10/18

The Safety/Tolerability and Pharmacokinetics (PKs) of Naftopidil in Korean Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00967772 Org: User:
Start: 09/30/09 End: 03/31/10 Due: 03/31/11

Clinical Trial of DA-5212 in Patients with Functional Dyspepsia

Phase: N/A Priority: Normal
NCT ID: NCT05842408 Org: User:
Start: 06/06/23 End: 09/04/24 Due: 09/04/25

Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06993181 Org: User:
Start: 06/30/25 End: 07/31/25 Due: 07/31/26

A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT07007533 Org: User:
Start: 06/30/25 End: 07/31/25 Due: 07/31/26

A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT07027982 Org: User:
Start: 06/30/25 End: 08/31/25 Due: 08/31/26

A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants

Phase: N/A Priority: Normal
NCT ID: NCT06391827 Org: User:
Start: 05/07/24 End: 05/31/25 Due: 05/31/26

A Study to Evaluate the Food Effect on the Pharmacokinetics of DA-5223 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT07007520 Org: User:
Start: 06/30/25 End: 08/31/25 Due: 08/31/26

Bioequivalence Study Between "Dong-A Atorvastatin Tab" and "Lipitor Tab"

Phase: N/A Priority: Normal
NCT ID: NCT04325009 Org: User:
Start: 03/30/20 End: 08/31/20 Due: 08/31/21

A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab.

Phase: N/A Priority: Normal
NCT ID: NCT01817556 Org: User:
Start: 10/31/12 End: 10/31/13 Due: 10/31/14

Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating DA-3031 (PEG-G-CSF) to Filgrastim (Dong-A) in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00959777 Org: User:
Start: - End: - Due: -

Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

Phase: N/A Priority: Normal
NCT ID: NCT04798690 Org: User:
Start: 02/08/21 End: 12/31/31 Due: 12/31/32

Safety and Efficacy of DA-9805 for Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03189563 Org: User:
Start: 02/06/18 End: 04/10/19 Due: 04/10/20

Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)

Phase: N/A Priority: Normal
NCT ID: NCT01553721 Org: User:
Start: 08/31/11 End: 03/31/15 Due: 03/31/16

Efficacy and Safety of DA-3002 in Short Children Borns SGA.

Phase: N/A Priority: Normal
NCT ID: NCT02770157 Org: User:
Start: 02/26/16 End: 08/28/19 Due: 08/28/20

Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229

Phase: N/A Priority: Normal
NCT ID: NCT02267902 Org: User:
Start: 09/30/14 End: 01/31/15 Due: 01/31/16

A Clinical Study to Assess the Efficacy and Safety of DA-3002

Phase: N/A Priority: Normal
NCT ID: NCT01813630 Org: User:
Start: 02/28/13 End: 05/31/18 Due: 05/31/19